← Browse by Condition
Medical Condition

acute myeloid leukemia with flt3 itd mutation

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1
NCT06222580 Phase 1
Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Enrollment
30 pts
Location
United States
Sponsor
Uma Borate
View Trial →